Gavreto
Named-patient access overview. Gavreto is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Gavreto (pralsetinib) is a selective RET (rearranged during transfection) kinase inhibitor approved by the US Food and Drug Administration in September 2020 for RET fusion-positive metastatic non-small cell lung cancer, in December 2020 for RET-mutant medullary thyroid cancer in patients 12 years and older, and for RET fusion-positive thyroid cancers refractory to radioactive iodine. The product is marketed approximately by Genentech in collaboration with Blueprint Medicines.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Gavreto
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Gavreto is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Gavreto in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Gavreto
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.